CS MEDICA A/S: Statement of Extraordinary General Meeting

Today on June 30, 2023, in Copenhagen - CS MEDICA A/S (”CS MEDICA” or “The Company”) held an extraordinary general meeting (“EGM”) at which the following principal resolutions were passed

Approval of the proposal of New Board Member
The EGM was resolved in accordance with the Board of Directors’ proposal whereafter Alexandre Fevre steps down, and Karsten Adelmark assumes a position as board member. 

The total number of votes as of the date of this Statement is 12,322,635, whereof 74 %%, equal to 9.143.701, votes were represented at the EGM.

The resolutions were approved unanimously by all shareholders represented at the EGM.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company operating globally within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments with CBD for autoimmune and stress-related disorders under the trademark CANNASEN® or own-label options. 

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com, and LinkedIn.

Taggar: